Prevalence of HPV (Human Papilloma Virus) and HPV Vaccination Among Victims of Sexual Violence
Conditions: Human Papilloma Virus; Sexual Assault; Sex Abuse Interventions: Diagnostic Test: smears Sponsors: Centre Hospitalier Universitaire Saint Pierre; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors
Conditions: Advanced Solid Tumors Interventions: Biological: MK-1200; Drug: Antiemetic Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
Validation of Donor Oocytes Semi-automated Vitrification
Conditions: Vitrification; Egg Donor; Fertility; Assisted Reproductive Technology Interventions: Device: Gavi, Merck ® (automated vitrification instrument); Device: Vitrolife system Sponsors: University Hospital, Clermont-Ferrand Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
A Study of HC-7366 in Combination With Belzutifan (WELIREG ™) in Patients With Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma Interventions: Drug: HC-7366; Drug: Belzutifan Sponsors: HiberCell, Inc.; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
Conditions: Human Papilloma Virus Interventions: Biological: Gardasil 9 Sponsors: University of Alabama at Birmingham; Merck Investigator Studies Program Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
Muscle Relaxation for Pediatric Adenotonsillectomy
Conditions: Tonsillectomy Interventions: Drug: Rocuronium; Drug: Sugammadex; Other: Anesthesia without neuromuscular blockade Sponsors: University of Texas Southwestern Medical Center; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
Conditions: Metastatic Non-small Cell Lung Cancer Interventions: Biological: Pembrolizumab coformulated with hyaluronidase; Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin; Drug: Paclitaxel; Drug: Nab-paclitaxel; Biological: Pembrolizumab Sponsors: Merck Sharp& Dohme LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials
Study to Evaluate the Efficacy and Safety of Cetuximab in Combination With Encorafenib Plus Binimetinib as Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer
Conditions: Colorectal Cancer Interventions: Drug: EBC Sponsors: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD); Merck, S.L., Spain; Pierre Fabre Ib érica, S.A. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer Interventions: Drug: Ifinatamab deruxtecan; Drug: Topotecan; Drug: Amrubicin; Drug: Lurbinectedin Sponsors: Daiichi Sankyo, Inc.; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Conditions: Chronic Heart Failure With Reduced Ejection Fraction Interventions: Drug: Vericiguat (BAY1021189) 5 mg Sponsors: Bayer; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
Conditions: Endometrial Cancer Interventions: Drug: Pembrolizumab Injection [Keytruda] Sponsors: University Medical Center Groningen; Merck Sharp& Dohme LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2023 Category: Research Source Type: clinical trials
Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
Conditions: Narcolepsy Interventions: Drug: MK-6552; Drug: Placebo Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 21, 2023 Category: Research Source Type: clinical trials
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
Conditions: Pneumococcal Infection Interventions: Biological: V116; Biological: PPSV23 Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials
FDA Grants Priority Review to Merck ’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
Acceptance based on results from multiple Phase 3 trials
If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults
The 21 serotypes covered by V116 are responsible for approximately 83% of invasive... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 19, 2023 Category: Pharmaceuticals Source Type: clinical trials
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Conditions: Advanced Solid Tumor; Melanoma; Head and Neck Cancer; Gastric Cancer Interventions: Drug: HER3-DXd Sponsors: Daiichi Sankyo, Inc.; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2023 Category: Research Source Type: clinical trials
